Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01212471 · ClinicalTrials.gov registry record · Phase 3
A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 840
- Enrollment target
NCT01212471: Completed Phase 3 study, sponsored by Bausch & Lomb Incorporated.
NCT01212471 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 840 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01212471, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 840 participants
- Enrollment target
Study Summary
A dose ranging study to evaluate safety and efficacy of bromfenac ophthalmic solution in dry eye disease.
Primary Outcome
The Ocular Surface Disease Index (OSDI) is a 12 item questionnaire. Each question about discomfort/limitations is scored from 0 to 4, with 0 being 'None of the Time' and 4 being 'All of the Time'. The minimum total score is 0 and the maximum total score is 48, with higher scores indicating worse outcomes.
Interventions
- DRUG Placebo Comparator
- DRUG Bromfenac Ophthalmic Solution A
- DRUG Bromfenac Ophthalmic Solution B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 840 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
What the finished NCT01212471 record still lists
NCT01212471 is an interventional study that assigns participants to a tested intervention. The registered 840 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Placebo Comparator is the first listed.
NCT01212471 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01212471 about?
NCT01212471 is a clinical study titled "A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease". A dose ranging study to evaluate safety and efficacy of bromfenac ophthalmic solution in dry eye disease.
What is the current status of trial NCT01212471?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 840 participants. The study started on 2010-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01212471?
The interventions under investigation include: Placebo Comparator (DRUG), Bromfenac Ophthalmic Solution A (DRUG), Bromfenac Ophthalmic Solution B (DRUG).
Who is sponsoring clinical trial NCT01212471?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01212471's enrollment target sits among peer trials
840 392nd of 2000 higher than 1,607 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04831580 · 840 participants · NA
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
- NCT04976881 · 840 participants · NA
Promoting Preconception Care and Diabetes Self-Management Among Reproductive-Aged Women With Diabetes
- NCT04985903 · 840 participants · NA
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
- NCT05384626 · 840 participants · Phase 1
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia